Previous 10 | Next 10 |
SANTA CLARA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter of 2022 after market close on Monday, Fe...
SI-Bone ( NASDAQ: SIBN ) expects Q4 worldwide revenue to be in the range of $31.7M-$31.9M, representing growth of ~26% Y/Y, vs consensus of $30.05M . Q4 U.S. revenue expected to be in the range of $29.8M-$29.9M, representing growth of ~28% Y/Y. The company end...
Fourth Quarter revenue of $31.7 - $31.9 million representing growth of approximately 26% Fiscal Year 2022 revenue of $106.1 - $106.3 million representing growth of approximately 18% SANTA CLARA, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device c...
SANTA CLARA, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 25th Annual Needham Growth Conference. Ma...
Summary SI-BONE, Inc. presents as a niche operator in the surgical intervention of sacroiliac disorders. There are multiple inflection points on the horizon for SI-BONE in FY 2023. Market punishment has been severe for SI-BONE, Inc. stock over 2021-2022, however, a contrarian view i...
Medical device maker SI-BONE ( NASDAQ: SIBN ) announced Tuesday that the FDA cleared additional indications for its iFuse Bedrock Granite spinal implant allowing its use with a wide range of commercial products. iFuse Bedrock Granite is used to immobilize and fuse the sacroiliac (SI) ...
SANTA CLARA, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced an additional FDA clearance for iFuse Bedrock Granite ® . Ne...
SI-BONE, Inc. (SIBN) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants ...
SI-BONE press release ( NASDAQ: SIBN ): Q3 GAAP EPS of -$0.41 beats by $0.07 . Revenue of $26.43M (+18.5% Y/Y) in-line. The Company expects 2022 worldwide revenue to be in the range of $104 million to $105 million vs $107.13M consensus, implying growth of appro...
SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2022. Recent Highlights ...
News, Short Squeeze, Breakout and More Instantly...
SANTA CLARA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2024 after market close on Monday, Au...
2024-07-04 13:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-14 15:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...